BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 37144587)

  • 41. HPV testing with cytology triage for cervical cancer screening in routine practice.
    Louvanto K; Chevarie-Davis M; Ramanakumar AV; Franco EL; Ferenczy A
    Am J Obstet Gynecol; 2014 May; 210(5):474.e1-7. PubMed ID: 24373948
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Urine collection in cervical cancer screening - analytical comparison of two HPV DNA assays.
    Tranberg M; Jensen JS; Bech BH; Andersen B
    BMC Infect Dis; 2020 Dec; 20(1):926. PubMed ID: 33276740
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinical evaluation of modifications to a human papillomavirus assay to optimise its utility for cervical cancer screening in low-resource settings: a diagnostic accuracy study.
    Kuhn L; Saidu R; Boa R; Tergas A; Moodley J; Persing D; Campbell S; Tsai WY; Wright TC; Denny L
    Lancet Glob Health; 2020 Feb; 8(2):e296-e304. PubMed ID: 31981559
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cervical human papilloma virus (HPV) DNA primary screening test: Results of a population-based screening programme in central Italy.
    Passamonti B; Gustinucci D; Giorgi Rossi P; Cesarini E; Bulletti S; Carlani A; Martinelli N; Broccolini M; D'Angelo V; D'Amico MR; Di Dato E; Galeazzi P; Malaspina M; Spita N; Tintori B; Giaimo MD
    J Med Screen; 2017 Sep; 24(3):153-162. PubMed ID: 27614992
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Screening for persistent high-risk HPV infections may be a valuable screening method for young women; A retrospective cohort study.
    Ebisch RMF; Ketelaars PJW; van der Sanden WMH; Schmeink CE; Lenselink CH; Siebers AG; Massuger LFAG; Melchers WJG; Bekkers RLM
    PLoS One; 2018; 13(10):e0206219. PubMed ID: 30356297
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Health technology assessment report: HPV DNA based primary screening for cervical cancer precursors].
    Ronco G; Biggeri A; Confortini M; Naldoni C; Segnan N; Sideri M; Zappa M; Zorzi M; Calvia M; Accetta G; Giordano L; Cogo C; Carozzi F; Gillio Tos A; Arbyn M; Mejier CJ; Snijders PJ; Cuzick J; Giorgi Rossi P
    Epidemiol Prev; 2012; 36(3-4 Suppl 1):e1-72. PubMed ID: 22828243
    [TBL] [Abstract][Full Text] [Related]  

  • 47. HPV detection rates and histopathologic follow-up of patients with HSIL cytology in a large academic women's hospital laboratory.
    Ashman D; Zhang H; Li J; Austin M; Wang T; Pradhan D; Zhao C
    J Am Soc Cytopathol; 2020; 9(6):550-555. PubMed ID: 32475726
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical performance of primary HPV screening cut-off for colposcopy referrals in HPV-vaccinated cohort: Observational study.
    Beecroft M; Gurumurthy M; Cruickshank ME
    BJOG; 2023 Jan; 130(2):210-213. PubMed ID: 36054732
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral.
    Kulasingam SL; Hughes JP; Kiviat NB; Mao C; Weiss NS; Kuypers JM; Koutsky LA
    JAMA; 2002 Oct; 288(14):1749-57. PubMed ID: 12365959
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Performance of alternative strategies for primary cervical cancer screening in sub-Saharan Africa: systematic review and meta-analysis of diagnostic test accuracy studies.
    Fokom-Domgue J; Combescure C; Fokom-Defo V; Tebeu PM; Vassilakos P; Kengne AP; Petignat P
    BMJ; 2015 Jul; 351():h3084. PubMed ID: 26142020
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Use of Multiplex Polymerase Chain Reaction for Detection of High-Risk Human Papillomavirus Genotypes in Women Attending Routine Cervical Cancer Screening in Harare.
    Marembo T; Dube Mandishora R; Borok M
    Intervirology; 2019; 62(2):90-95. PubMed ID: 31412350
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The Influence of Human Papillomavirus Genotypes on Visual Screening and Diagnosis of Cervical Precancer and Cancer.
    Jeronimo J; Bansil P; Valdez M; Kang LN; Zhao FH; Qiao YL; Chen W; Zhang X; Paul P; Bai P; Peck R; Li J; Chen F; Stoler MH; Castle PE
    J Low Genit Tract Dis; 2015 Jul; 19(3):220-3. PubMed ID: 25279978
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The impact of age and high-risk human papillomavirus (hrHPV) status on the prevalence of high-grade cervical intraepithelial neoplasia (CIN2+) in women with persistent hrHPV-positive, cytology-negative screening samples: a prospective cohort study.
    Tidy JA; Lyon R; Ellis K; Macdonald M; Palmer JE
    BJOG; 2020 Sep; 127(10):1260-1267. PubMed ID: 32279427
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prevalence of genital high-risk human papillomavirus infections and associated factors among women living with human immunodeficiency virus in Uganda.
    Nakigozi H; Ndejjo R; Bazeyo W; Nabaggala A; Achola C; Iga M; Kalyesubula S; Kanamwangi B; Mutungi G; Batte C; Mukunya D; Sserwanga L; Gemageine G; Oyoo CA; Nabadda S
    BMC Cancer; 2024 Feb; 24(1):243. PubMed ID: 38383366
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Primary cervical cancer screening with human papillomavirus: end of study results from the ATHENA study using HPV as the first-line screening test.
    Wright TC; Stoler MH; Behrens CM; Sharma A; Zhang G; Wright TL
    Gynecol Oncol; 2015 Feb; 136(2):189-97. PubMed ID: 25579108
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Protocol for Compass: a randomised controlled trial of primary HPV testing versus cytology screening for cervical cancer in HPV-unvaccinated and vaccinated women aged 25-69 years living in Australia.
    Canfell K; Saville M; Caruana M; Gebski V; Darlington-Brown J; Brotherton J; Heley S; Castle PE
    BMJ Open; 2018 Jan; 8(1):e016700. PubMed ID: 29374658
    [TBL] [Abstract][Full Text] [Related]  

  • 57. PCR-reverse dot blot human papillomavirus genotyping as a primary screening test for cervical cancer in a hospital-based cohort.
    Kang Y; Sun P; Mao X; Dong B; Ruan G; Chen L
    J Gynecol Oncol; 2019 May; 30(3):e29. PubMed ID: 30887754
    [TBL] [Abstract][Full Text] [Related]  

  • 58. VALHUDES: A protocol for validation of human papillomavirus assays and collection devices for HPV testing on self-samples and urine samples.
    Arbyn M; Peeters E; Benoy I; Vanden Broeck D; Bogers J; De Sutter P; Donders G; Tjalma W; Weyers S; Cuschieri K; Poljak M; Bonde J; Cocuzza C; Zhao FH; Van Keer S; Vorsters A
    J Clin Virol; 2018 Oct; 107():52-56. PubMed ID: 30195193
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical Performance of Human Papillomavirus Testing and Visual Inspection With Acetic Acid in Primary, Combination, and Sequential Cervical Cancer Screening in China.
    Wang MZ; Feng RM; Wang S; Duan XZ; Li D; Zhang X; Mu R; Qiao Y; Smith JS
    Sex Transm Dis; 2019 Aug; 46(8):540-547. PubMed ID: 31295223
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Human papillomavirus E7 protein detection as a method of triage to colposcopy of HPV positive women, in comparison to genotyping and cytology. Final results of the PIPAVIR study.
    Agorastos T; Chatzistamatiou K; Moysiadis T; Kaufmann AM; Skenderi A; Lekka I; Koch I; Soutschek E; Boecher O; Kilintzis V; Angelidou S; Katsiki E; Hagemann I; Boschetti Gruetzmacher E; Tsertanidou A; Angelis L; Maglaveras N; Jansen-Duerr P
    Int J Cancer; 2017 Aug; 141(3):519-530. PubMed ID: 28470689
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.